![Page 1: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/1.jpg)
The Intravenous Immunoglobulins: Current and
Future Role in the NICU Could IVIG be neuro-protective?
William Tarnow-MordiProfessor of Neonatal Medicine
University of SydneyWestmead Hospital and The Children’s
Hospital at Westmead
![Page 2: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/2.jpg)
OFF LABEL DISCLOSURE
William Tarnow-Mordi has documented that his presentation involves comments or discussion of unapproved or off-label, experimental or investigational use of
(a) polyclonal intravenous immunoglobulin (IVIG)
(b) Veronate (anti-staphylococcal immunoglobulin)
![Page 3: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/3.jpg)
DISCLOSURE STATEMENT
Dr. William Tarnow-Mordi has documented that he has nothing else to disclose.
![Page 4: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/4.jpg)
MISSION STATEMENT
The primary aim of clinical studies in the newborn is to identify interventions that increase disability-free survival, employing the most reliable evidence from RCTs.
![Page 5: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/5.jpg)
OUTLINE
![Page 6: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/6.jpg)
Current role of IVIG
(a) Immunomodulatory properties of IVIG
(b) Thrombocytopenia
(b) Haemolytic disease
(c) Infection
![Page 7: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/7.jpg)
Future potential role of IVIG
Is IVIG neuro-protective in newborns with, or at risk of, infection?
![Page 8: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/8.jpg)
Future role of IVIG
1. Do neonatal infections remote from the brain, including CONS, cause brain damage?
2. Are white matter damage and periventricular leukomalacia partly immune-mediated?
![Page 9: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/9.jpg)
3. Is multiple sclerosis (and its animal model) a model for PVL?
4. Can IVIG promote re-myelination in multiple sclerosis and other CNS inflammatory states?
5. Can we do trials big enough to test reliably if
IVIG is neuro-protective in newborns with, or at risk of, infection?
![Page 10: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/10.jpg)
Current role of IVIG
(a) Immunomodulatory properties of IVIG
(b) Thrombocytopenia
(b) Haemolytic disease
(c) Infection
![Page 11: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/11.jpg)
![Page 12: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/12.jpg)
![Page 13: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/13.jpg)
Pro-inflammatory• opsonic activity
• fixation of complement
• antibody dependent cytotoxicity
• neutrophil chemiluminescence
• phagocytosis
• release of stored neutrophils
![Page 14: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/14.jpg)
““The phagocytes won’t eat the The phagocytes won’t eat the microbes unless the microbes microbes unless the microbes are nicely buttered for them. are nicely buttered for them.
Well, the patient manufactures Well, the patient manufactures the butter himself alright, but the butter himself alright, but
my discovery is that the my discovery is that the manufacture of that butter, manufacture of that butter,
which I call OPSONIN, goes in which I call OPSONIN, goes in the system by ups and down.the system by ups and down.
There is at the bottom only one There is at the bottom only one genuinely scientific treatment genuinely scientific treatment for all diseases, and that is to for all diseases, and that is to
stimulate phagocytosis”.stimulate phagocytosis”. Dr Ridgeon Dr Ridgeon
The Doctor’s DilemmaThe Doctor’s DilemmaG B Shaw 1909G B Shaw 1909
![Page 15: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/15.jpg)
Anti-inflammatoryDown-regulation of inflammatory cytokines via
• Fc receptor blockade, • provision of anti-idiotype antibodies• interference with activation of
– T-cells – B-cells – the cytokine network– complement
Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.
Kazatchkine MD,. et al. N Engl J Med 2001
![Page 16: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/16.jpg)
![Page 17: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/17.jpg)
Current role of IVIG
(a) Immunomodulatory properties of IVIG
(b) Thrombocytopenia
(b) Haemolytic disease
(c) Infection
![Page 18: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/18.jpg)
Neonatal alloimmune/ autoimmune thrombocytopenia
• Incidence 1 per 1000
• First reports of IVIG in 1980s
• No RCTs
![Page 19: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/19.jpg)
Immune-mediated thrombocytopenia (Idiopathic thrombocytopenia - ITP)
• Extremely rare in newborns
• First reports of IVIG in 1981
• Subsequently effective in RCTs
• FDA approved
![Page 20: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/20.jpg)
Current role of IVIG
(a) Immunomodulatory properties of IVIG
(b) Thrombocytopenia
(b) Haemolytic disease
(c) Infection
![Page 21: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/21.jpg)
IVIG for Rhesus disease and ABO incompatibility:Two systematic reviews of the same data
1. Alcock GS, Liley H. Cochrane Review 2002
2. Gottstein R, Cooke RW. Arch Dis Child Fetal Neonatal 2003
In 3 RCTs in 199 infants, IVIG led to• Fewer exchange transfusions
– Relative Risk 0.28 (0.17 – 0.47)
• Shorter phototherapy and hospital stay• No data on disability-free survival
![Page 22: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/22.jpg)
Reduced need for exchange transfusion with IVIG vs standard treatment for haemolytic jaundice:
Number needed to treat 2.7 (95% CI 2.0 to 3.8).
![Page 23: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/23.jpg)
Similar results: differing conclusions
Alcock GS, Liley H. Cochrane Review 2002
‘Well designed studies are needed before routine use of IVIG can be recommended.’
Gottstein R, Cooke RWI. Arch Dis Child Fetal Neonatal 2003
‘IVIG is an effective treatment.’
![Page 24: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/24.jpg)
Mechanisms of action of IVIG in ITP and haemolytic jaundice
• Similar mechanisms are postulated for effects of IVIG in both conditions.
• They are incompletely understood.
![Page 25: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/25.jpg)
Plat
Macrophage
Theory 1: IVIG (Fab portion – fork end) binds sensitised red cells. IVIG Fc portion (fork handle) blocks the Fc receptor on macrophages
Possible mechanisms of IVIG in ITP
Fehr et al, 1982
![Page 26: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/26.jpg)
Theory 2: IVIG upregulates inhibitory FcγRIIB receptors on macrophages. This inhibits phagocytosis.
Macrophage
Plat
?
FcγRIII or IIA
↑ FcγRIIB expression
Possible mechanisms of IVIG in ITP
Samuelsson et al, 2001
![Page 27: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/27.jpg)
Current role of IVIG
(a) Immunomodulatory properties of IVIG
(b) Thrombocytopenia
(b) Haemolytic disease
(c) Infection
![Page 28: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/28.jpg)
(c) Infection
• Therapeutic IVIG
• Prophylactic polyclonal IVIG
• Prophylactic hyper-immune IVIG (Veronate) to prevent staphylococcal infection
![Page 29: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/29.jpg)
Therapeutic IVIGTwo Cochrane reviews
1. IVIG for treating sepsis and septic shock
Alejandria MM, Lansang MA, Dans LF, Mantaring JBV.
2. Polyclonal IVIG for suspected or subsequently proven infection in neonates
Ohlsson A, Lacy JB.
![Page 30: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/30.jpg)
1. IVIG for treating sepsis and septic shock Alejandria MM, Lansang MA, Dans LF, Mantaring JBV.
Polyclonal IVIG reduces mortality in all age groups combined
n=492
Relative Risk 0.64 (0.64 – 0.80)
p = 0.00009
![Page 31: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/31.jpg)
1. IVIG for treating sepsis and septic shock Alejandria MM, Lansang MA, Dans LF, Mantaring JBV.
![Page 32: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/32.jpg)
1. IVIG for treating sepsis and septic shock Alejandria MM, Lansang MA, Dans LF, Mantaring
JBV.
• No mortality reduction with anti-cytokine or monoclonal IVIG
• Anti-cytokine IVIG (4 RCTs, n =4,318)– RR=0.93; 95% CI 0.86 to 1.01); NS
• Monoclonal IVIG (5 RCTs, n= 2,826)– RR=0.97; (95% CI 0.88 to 1.07); NS
![Page 33: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/33.jpg)
2. Polyclonal IVIG for suspected or subsequently proven infection in neonates
Ohlsson A, Lacy JB. Cochrane Review 2004
mortality reduced in suspected infection, but with borderline statistical significance
n = 318; Relative Risk 0.63 (95% CI; 0.40 - 1.00); p = 0.05
mortality reduced in subsequently proved infection, but with wide confidence interval
n = 262; Relative Risk 0.55 (95% CI 0.31, 0.98); p = 0.04
![Page 34: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/34.jpg)
2. Polyclonal IVIG for suspected or subsequently proven infection in neonates
Ohlsson A, Lacy JB. Cochrane Review 2004
• Insufficient evidence for routine IVIG.
Well-designed trials to assess long term disability and cost effectiveness are needed.
• One such trial is the International Neonatal Immunotherapy Study.
![Page 35: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/35.jpg)
(c) Infection
• Therapeutic IVIG
• Prophylactic polyclonal IVIG
• Prophylactic hyper-immune IVIG (Veronate) to prevent staphylococcal infection
![Page 36: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/36.jpg)
Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants
Ohlsson A, Lacy JB. Cochrane Review 2004.
• 16 RCTs of IVIG versus placebo or no intervention • ~ 5,000 infants < 37 weeks gestation or <2500 g
• 3-4% reduction in sepsis or serious infection
![Page 37: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/37.jpg)
Cumulative meta-analysis: IVIG vs Placebo or No Treatment
Relative Risk 0.82 (95% CI 0.74-0.92) Risk Difference 0.04 (95% CI 0.02, 0.06)
![Page 38: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/38.jpg)
Polyclonal IVIG prophylaxis
• Reduces infection by 3-4% – statistically significant– marginal clinical significance
• No reductions in mortality, or– NEC, IVH – hospital stay
• No short term serious side effects
• Inconclusive on disability-free survival
![Page 39: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/39.jpg)
Conclusions
• No further RCTs of standard IVIG to prevent infections
• Basic scientists and clinicians should pursue other avenues
![Page 40: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/40.jpg)
(c) Infection
• Therapeutic IVIG
• Prophylactic polyclonal IVIG
• Prophylactic hyper-immune IVIG (Veronate) to prevent staphylococcal infection
![Page 41: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/41.jpg)
Veronatedata courtesy of Dr Seth Hetherington
• Intravenous Immune globulin
• Donors selected for high titers to:– Clumping factor A – S. aureus – Serine-aspartate repeat G protein – S.
epidermidis
• Antibodies block attachment of bacteria to fibrinogen
![Page 42: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/42.jpg)
Prophylactic hyperimmune anti-staphylococcal IVIG (Veronate): 2017 infants Bwt 500- 1250 g
Blood Stream Infection Control Veronaten = 989 n = 994
Staph aureus 5% 6%
Probable CONS 16% 15%
Definitive CONS 9% 11%
Any Infection 35% 35%
Mortality 7% 6%
![Page 43: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/43.jpg)
Veronate
No difference was statistically significant
Including these data may not alter the result of the meta-analysis of prophylactic trials:~ 3-4% reduction in sepsis with prophylactic IVIG
Too early for data on disability-free survival
![Page 44: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/44.jpg)
Current use of IVIG in the NICU
• Based on promising, but incomplete, evidence of effectiveness in – Thrombocytopenia– Haemolytic jaundice– Neonatal sepsis
with no evidence of its long-term effects.
![Page 45: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/45.jpg)
Future role of IVIG
1. Do neonatal infections remote from the brain, including CONS, cause brain damage?
2. Are white matter damage and periventricular leukomalacia partly immune-mediated?
![Page 46: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/46.jpg)
![Page 47: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/47.jpg)
Leviton, Gillies, Neff, Yaney 1976
White matter damage, or perinatal telencephalic leuco-encephalopathy (PTL), was more common after gram negative septicaemia.
‘It is hypothesized that endotoxin from bacteria adversely affects developing white matter…’
![Page 48: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/48.jpg)
Stoll et al (JAMA) 2004
![Page 49: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/49.jpg)
Stoll, Hansen, Adams-Chapman, Fanaroff, Hintz, Vohr, Higgins, for the NICHD
Neonatal Research Network, JAMA 2004
• 6093 infants < 1000 g bwt assessed at 18 – 22 months corrected for gestation
![Page 50: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/50.jpg)
Neuro-developmental Impairment (NDI) in infected versus uninfected infants
Category N (%) NDI (unadjusted)
OR for NDI adjusted for 21 risk factors
uninfected 2161 (35) 29% -Culture neg clinical infection
1538 (25) 43% 1.3 (1.1-1.6)
Culture positive sepsis
1922 (32) 48% 1.5 (1.2 – 1.7)
Sepsis and NEC
279 (5) 53% 1.8 (1.4 – 2.5)
meningitis 193 (3) 48% 1.6 (1.1 – 2.3)
![Page 51: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/51.jpg)
Neuro-developmental impairment in infants with different pathogens versus uninfected infants
Category N % NDI (unadjusted)
Adjusted OR for NDI relative to uninfected
uninfected 1976 29% -CONS 853 44% 1.3 (1.1 – 1.6)
Other Gm pos
256 48% 1.7 (1.2 – 2.3)
Gram negative
185 45% 1.8 (1.2 – 7.6)
Fungal 96 57% 1.4 (0.9 – 2.2)
![Page 52: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/52.jpg)
After adjustment for antenatal, perinatal and postnatal factors
Neonatal infection, including CONS and culture-negative sepsis, was associated with increases of 30 – 80% in the odds of
• poor head growth (< 10th centile) at – 36 weeks– 18-22 months
• neuro-developmental impairment at 18-22 months
![Page 53: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/53.jpg)
• CONS– although less clinically severe– may be associated with more disability than
any other pathogen (n=853)
• Culture-negative clinical infection – potentially more important than CONS in its
association with disability (n=1538)
![Page 54: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/54.jpg)
Association or causality? RCTs are needed to prove cause and effect
• Neonatal infection may – cause neuro-developmental impairment, or– share a common cause with NDI
• If RCTs (e.g. of IVIG) in neonatal infection – show a reduction in disability– this would confirm infection as causal.
![Page 55: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/55.jpg)
Association between cerebral palsy and coagulase-negative staphylococci.
Mittendorf et al. Lancet 1999
• Cultured amnion-chorion space in 107 preterm infants.
• 35% grew no organisms. 28% grew CONS
• CONS isolated in 4/5 (80%) infants who later manifest CP vs 26/102 (25%) who did not. (p<0.02)
![Page 56: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/56.jpg)
Mittendorf et al. Lancet 1999
• Small study, possible chance association
• Consistent with hypotheses that– CONS may be causal in Cerebral Palsy– mediated by virulence factors such as
haemolysins, deoxyribonuclease, slime and adhesins
![Page 57: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/57.jpg)
Future role of IVIG
1. Do neonatal infections remote from the brain, including CONS, cause brain damage?
2. Are white matter damage and periventricular leukomalacia partly immune-mediated?
![Page 58: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/58.jpg)
Zupan et al, 1996; Volpe, 1997,2001
• Focal, cystic PVL:– more severe, becoming less frequent – progressive loss of all cells in white matter.
• Diffuse PVL – less severe, increasingly frequent– mainly affects developing oligodendrocytes
![Page 59: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/59.jpg)
Nitrosative and oxidative injury to premyelinating oligodendrocytes in PVL
Haynes RL, et al. J Neuropathol Exp Neurol 2003
Autopsied 17 PVL cases and 28 non-PVL controls.
Diffuse PVL involves injury to premyelinating oligodendrocytes through
– activation of microglia – release of reactive oxygen and nitrogen species
![Page 60: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/60.jpg)
Infection remote from the brain, neonatal white matter damage, and cerebral palsy in the preterm infant.
Damman O, Leviton A. 1998
Remote infection could
– lead to an inflammatory response that may be responsible for initiating and prolonging tissue injury
– induce white matter damage by molecular mechanisms, especially cytokines.
.
![Page 61: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/61.jpg)
![Page 62: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/62.jpg)
![Page 63: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/63.jpg)
Fetal / neonatal cytokinemia and white cell activation in WMD
Duggan et al, Lancet 2001
50 infants 23-29 weeks gestation: cord blood
- for cytokines
- CD45RO T lymphocytes (to assess T cell
activation)
Brain MRI done at median 2 days after birth
• 18 (36%) had cerebral lesions associated with
• ↑ cytokines and % activated T cells
![Page 64: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/64.jpg)
![Page 65: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/65.jpg)
![Page 66: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/66.jpg)
Duggan et al, Lancet 2001
Immune cells might be directly involved in injury
Activated CD45RO+ T lymphocytes express
– activation, homing and adhesion molecules– migrate into tissues – induce apoptosis
![Page 67: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/67.jpg)
![Page 68: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/68.jpg)
![Page 69: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/69.jpg)
The Toll-like receptor TLR4 is necessary for LPS induced oligodendrocyte injury in the CNS
Lehnardt et al. J Neuroscience 2002
To exert its pathogenic effect, LPS requires TLR4, a receptor present on
– circulating monocytes/ macrophages – other systemic immune cells– microglia in the CNS.
![Page 70: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/70.jpg)
LPS (endotoxin) kills oligodendrocytes only when microglia are present in culture
![Page 71: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/71.jpg)
The Toll-Like Receptor TLR4 Is Necessary for Lipopolysaccharide- induced Oligodendrocyte Injury in CNS
Lehnardt et al 2002
Provides a mechanism of action between
(1) LPS (and other microbial antigens)
↓
(2) induction of innate, non-specific immunity
↓
(2) injury to oligodendrocytes and myelin
(as in PVL and multiple sclerosis).
![Page 72: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/72.jpg)
3. Is multiple sclerosis (and its animal model) a model for PVL?
4. Can IVIG promote re-myelination in multiple sclerosis and other CNS inflammatory states?
5. Can we do trials big enough to test reliably if
IVIG is neuro-protective in newborns with, or at risk of, infection?
![Page 73: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/73.jpg)
Histological appearance of Multiple Sclerosis
• Demyelination of nerve axons, mostly in white matter, with acute focal inflammatory changes.
• Lesions include – axonal loss– spontaneous re-myelination– multifocal sclerotic plaques.
![Page 74: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/74.jpg)
Spontaneous remyelination in Multiple Sclerosis Perier O, Gregoire A. Brain 1965.
![Page 75: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/75.jpg)
Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis
Chang et al NEJM 2002
Oligodendrocyte progenitor cells characterized in
– developing brain– normal adult human brain– chronic lesions of multiple sclerosis.
![Page 76: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/76.jpg)
Spinal cord axons in the healthy mouse
Normally myelinated axons.
![Page 77: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/77.jpg)
Spinal cord axons after infection with Theiler’s murine encephalo-myelitis virus (TMEV)
• Extensive demyelination
• Some spontaneous remyelination.
• Macrophages/ microglia with ingested myelin debris (arrows).
![Page 78: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/78.jpg)
Recruitment of T lymphocytes across Blood Brain Barrier endothelium in MS and TME Virus infection
Engelhardt J Neural Transmission 2006
![Page 79: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/79.jpg)
3. Is multiple sclerosis (and its animal model) a model for PVL?
4. Can IVIG promote re-myelination in multiple sclerosis and other CNS inflammatory states?
5. Can we do trials big enough to test reliably if
IVIG is neuro-protective in newborns with, or at risk of, infection?
![Page 80: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/80.jpg)
Remyelination by oligodendrocytes stimulated by antiserum to spinal cord.
Rodriguez, M. J Neuropathol Exp Neurol. 1987
• Produced anti-serum from mice immunized with homogenized spinal cord (SCH).
• Anti-serum increased remyelination 10 fold in spinal cords after infection by TME virus.
![Page 81: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/81.jpg)
Human monoclonal antibodies reactive tooligodendrocytes promote remyelination in a model
of multiple sclerosis
Warrington et al PNAS 2000
Experiments with human remyelination-promoting mAbs in mice using normal human IVIG (IgG) as control
![Page 82: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/82.jpg)
Spinal cord axons in the healthy mouse
Normally myelinated axons – not infected with TMEV.
![Page 83: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/83.jpg)
Spinal cord axons after chronic infection with Theiler’s murine encephalo-myelitis virus
• Extensive demyelination
• Some spontaneous remyelination.
• Macrophages/ microglia with ingested myelin debris (arrows).
![Page 84: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/84.jpg)
Partial remyelination after infection with TME virus + treatment with monoclonal IgM
Significantly greater remyelination after treatment with monoclonal IgM
Same magnification
![Page 85: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/85.jpg)
Effect of IVIG on remyelination in mouse spinal cord after TME Virus infection
Warrington et al PNAS 2000
Treatment Group % Oligodendrocyte remyelination
P value
Controls 6.7 -
After human IVIG IgG
14.2 <0.05
After
Human IgM mAB
23.2 <0.001
![Page 86: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/86.jpg)
Human monoclonal antibodies reactive tooligodendrocytes promote remyelination in a model
of multiple sclerosis
Warrington et al PNAS 2000
% OL remyelination in mice was increased
– twofold with human IgG– fourfold with human IgM.
![Page 87: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/87.jpg)
Human monoclonal antibodies reactive tooligodendrocytes promote remyelination in a model
of multiple sclerosis
Warrington et al PNAS 2000 Human remyelination-promoting mAbs
• may be a simple, effective therapy.
• can be produced free of infectious agents
• may alleviate the high cost of IVIg.
• may simplify investigation of mechanisms of immunomodulatory therapies.
![Page 88: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/88.jpg)
Anti-apoptotic signaling by a remyelination-promoting human antimyelin antibody
Howe CL Neurobiol Dis 2004
In mice with TMEV, a recombinant hman monoclonal anti-myelin antibody
– induced anti-apoptotic signaling in premyelinating oligodendrocytes and
– reduced caspase-3 activation and caspase gene expression
![Page 89: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/89.jpg)
Anti-apoptotic signaling by a remyelination-promoting human antimyelin antibody
Howe CL, Neurobiology of Disease; 2004
Polyreactive autoantibodies that trigger repair within demyelinated lesions marked an important shift in our understanding of the role of antibodies in the CNS.
Recombinant monoclonal human IgM autoantibody rescued a pre-myelinating oligodendrocyte cell line from death induced by either hydrogen peroxide or TNF-a.
![Page 90: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/90.jpg)
Anti-apoptotic signaling by a remyelination-promoting human antimyelin antibody
Howe CL, Neurobiology of Disease; 2004
One mechanism by which IVIG may promote remyelination in CNS inflammatory conditions is by
– binding oligodendrocyte progenitors and
– preventing them from undergoing death induced by H2O2 of TNFα.
![Page 91: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/91.jpg)
CD54+ lymphocytes expressing ICAM-1 in blood from patients before and after IVIG
Créange et al. J Neuroimmunol 2003
![Page 92: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/92.jpg)
Cytokine expression by CSF monocytes in patients with Post Polio Syndrome after IVIG.
Gonzalez J Neuroimmunol 2004
↓ TNF-α (p < 0.05)
↓ IFN-γ (p < 0.001)
![Page 93: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/93.jpg)
• Is clinical evidence consistent with in vitro and in vivo laboratory evidence?
![Page 94: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/94.jpg)
Cochrane Reviews of IVIG in neurological
inflammatory conditions Condition No. of
patientsEffect
Multiple sclerosis 168 ↓ relapses (by 38-74%)
Guillain Barre syndrome 75 speeds recovery
Multifocal neuropathy 34 ↑ strength
Myasthenia Gravis 60 inconclusive
Chronic demyelinating inflammatory polyneuropathy
170 ↓ disability
![Page 95: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/95.jpg)
IVIG for the treatment of relapsing-remitting multiple sclerosis: a meta analysis.
Sorensen PS, Fazekas F, Lee M. Eur J Neurol 2002
![Page 96: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/96.jpg)
Achiron et al; Arch Neurol 2004
![Page 97: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/97.jpg)
Achiron et al; Arch Neurol 2004
Placebo controlled RCT of IVIG vs saline within 6 weeks of first signs of MS in 91 patients
36% lower probability of developing clinically definite multiple sclerosis –
– Risk ratio, 0.36
– 95% CI; 0.15- 0.88
– p = 0.03.
![Page 98: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/98.jpg)
Achiron et al; Arch Neurol 2004
The IVIG group had fewer MRI lesions at 12 months
– reduced volume T2-weighted (P =0.01)– fewer T2 weighted (P =0.01) of – reduced volume of gadolinium enhancing
lesions (P=0.03) .
![Page 99: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/99.jpg)
Achiron et al; Arch Neurol 2004
Future studies evaluating the combined effects of
– IVIG – interferons– glatiramer acetate
may offer additional benefit on the occurrence of second attack.
![Page 100: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/100.jpg)
These studies suggest that, in animals and adult humans, IVIG can reduce cerebral inflammation and ameliorate pre-existing cerebral lesions.
![Page 101: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/101.jpg)
3. Is multiple sclerosis a model for PVL?
4. Can IVIG promote re-myelination in multiple sclerosis and other CNS inflammatory states?
5. Can we do trials big enough to test reliably if
IVIG is neuro-protective in newborns with, or at risk of, infection?
![Page 102: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/102.jpg)
An ideal RCT to test if IVIG increases disability-free survival should
• randomise neonates to prophylactic, repeated IVIG or placebo.
• be large enough to detect realistically moderate differences with adequate power
• include long term follow up of – neuro-developmental and cognitive outcomes.
![Page 103: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/103.jpg)
International Neonatal Immunotherapy Study, INIS
[Google] npeu inis
www.npeu.ox.ac.uk/INIS.htm
(downloadable copy of this talk will be available)
![Page 104: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/104.jpg)
![Page 105: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/105.jpg)
International Neonatal Immunotherapy Study, INIS
A randomised placebo controlled trial of IVIG in proven or suspected neonatal sepsis
– Revised sample size 4,000 – to yield 90% power to detect a 5% risk
difference in death or major disability
![Page 106: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/106.jpg)
International Neonatal Immunotherapy Study, INIS
– 2 doses of 500 mg/ kg (total dose of 1 g/kg )– as an adjunct to antibiotic treatment
It does not therefore fulfil all the criteria for an ideal test of these hypotheses.
![Page 107: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/107.jpg)
However, …
Two multi-centre trials that provided more sustained doses of IVIG, for 2 weeks of more, have already been done, in a total of over 4,000 patients.
![Page 108: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/108.jpg)
![Page 109: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/109.jpg)
• 2416 infants < 72 hr after birth– stratified according to birth weight – (501-1000 g and 1001-1500 g)
• randomly assigned to fortnightly – prophylactic IVIG (n = 1204) or – control (n = 1212).
![Page 110: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/110.jpg)
• Prophylactic IVIG failed to reduce the incidence of hospital-acquired infections.
• These were 208 (17.3%) in the IVIG group and 231 (19.1%) in the control group
• (Relative Risk, 0.91; 95 percent confidence interval, 0.77 to 1.08).
![Page 111: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/111.jpg)
![Page 112: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/112.jpg)
![Page 113: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/113.jpg)
Prophylactic hyperimmune anti-staphylococcal IVIG (Veronate): 2017 infants Bwt 500- 1250 g
Blood Stream Infection Control Veronaten = 989 n = 994
Staph aureus 5% 6%
Probable CONS 16% 15%
Definitive CONS 9% 11%
Any Infection 35% 35%
Mortality 7% 6%
![Page 114: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/114.jpg)
Speculation
It would be valuable to determine the rates of neuro-developmental impairment in these randomised cohort, or subsets within them
To test the hypothesis that sustained IVIG therapy is (a) safe, (b) neuro-protective in neonates at risk of sepsis.
![Page 115: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/115.jpg)
Conclusions
Modulation of inflammation is a relatively new strategy for preventing or treating neurological injury.
New evidence is needed to evaluate IVIG as a non-steroidal anti-inflammatory agent that may reduce neonatal mortality and morbidity.
![Page 116: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/116.jpg)
Sir Richard Doll and Sir Richard Peto
![Page 117: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/117.jpg)
Sir Richard Doll Sir Richard Doll Controlled trials: the 1948 watershed Controlled trials: the 1948 watershed
BMJ 1998: 317: 1217-20BMJ 1998: 317: 1217-20
• “Early randomised trials (1940s) can properly be criticised on the grounds that they were often too small to have any chance of detecting moderate effects.
• “Small trials can be successful when the effect is large but this seldom occurs.“
![Page 118: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/118.jpg)
• “Only in the 1980s did it become possible to organise the groundbreaking international study of infarct survival (ISIS) trials…
• in tens of thousands of patients, which showed the value of moderate improvements in the treatment of common diseases.”
![Page 119: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/119.jpg)
The ISIS 1 Trial
• Atenolol infusion vs placebo after heart attack
• 16,000 patients recruited
• Showed a 2% mortality reduction- from 13% to 11%
![Page 120: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/120.jpg)
![Page 121: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/121.jpg)
The ISIS 2 Trial
• Aspirin vs placebo after heart attack
• 17,000 patients recruited
• Showed a 23% mortality reduction- from c. 11% to 8%.
![Page 122: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/122.jpg)
![Page 123: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/123.jpg)
The Goddess of Chance is a capricious mistress. Yet, with large enough numbers, she becomes our obedient servant – yielding up the truth.
Anon.
![Page 124: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/124.jpg)
Sample sizes to show Sample sizes to show moderate moderate or or largelarge differences differences in disability-free survival with 90% power at 2p = 0.05in disability-free survival with 90% power at 2p = 0.05
Adverse outcome in controls [C]%
Adverse outcome in treated group [T]%
Absolute risk difference
[C-T] %
Total sample needed (both groups combined)
Number needed to treat (NNT) to prevent one case
42 40 2 20, 712 50
42 39 3 9, 168 33
42 38 4 5,134 25
42 37 5 3,270 20
42 32 10 800 10
![Page 125: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/125.jpg)
• If newborns are to benefit from evidence as reliable as in cardiology,
• much larger numbers are needed–i.e. thousands, not hundreds
![Page 126: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/126.jpg)
A challenge
Judged by whether sufficient evidence exists to exclude moderate benefits or harms, most current perinatal treatments remain inadequately evaluated.
![Page 127: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/127.jpg)
A solution
• Samples of thousands, not hundreds, where the research question merits it
• Multicentre, international collaboration
• Prospective meta-analysis
• Simple, inexpensive modes of follow up
![Page 128: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/128.jpg)
Prospective meta-analysis
– Multiple trials with same design + hypotheses– Pledged to combine their results in a single, individual
patient based meta-analysis– New trials and hypotheses can be added before any
results are known– Avoids publication bias, data driven hypotheses– Combines the methodological advantages of a single
trial with pragmatic benefits of flexible funding arrangements and recognition needs of different national agencies
![Page 129: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/129.jpg)
International neonatal oxygen trials: NeoProm prospective meta-analysis
co-ordinator: Lisa Askie
Australia – 1200 – NHMRC*NZ - 300 – HRC*UK - 1200 – MRC*Canada- 1200 - CHIR*US - 1500 – NICHD US POSTUS - 1300 - NICHD SUPPORT*
*Already funded. Possible total = > 6,000
![Page 130: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/130.jpg)
Acknowledgments
PanelistsCarol J. Baker, Baylor College of Medicine, Houston, TXBarbara J. Stoll, Emory University School of Medicine, Atlanta, GALeonard E. Weisman, Baylor College of Medicine, Houston, TX
![Page 131: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/131.jpg)
Further acknowledgments
Alan Leviton, Arne Ohlsson, Olaf Damman, Peter Brocklehurst, Khalid Haque, David Isaacs, Wendy Hague, John Simes, Barbara Farrell, Priya Duggal-Beri, Ann Cust, David Henderson-Smart, Ben Stenson, David Edwards, Ryszard Lauterbach, Seth Hetherington, Amy Morris, Iain Chalmers, The Cochrane Collaboration and the hundreds of parents, babies, nursing and medical staff in over 100 hospitals worldwide who are contributing to the International Neonatal Immunotherapy Study (INIS) of polyclonal IVIG.
![Page 132: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/132.jpg)
![Page 133: William Tarnow-Mordi Professor of Neonatal Medicine University of Sydney](https://reader031.vdocuments.us/reader031/viewer/2022013004/5681451a550346895db1dc9b/html5/thumbnails/133.jpg)
William Silverman (‘Fumer’) 1917-2004
Taught his students and friends
• to consider the long term consequences of neonatal care, for patients and families
• to cultivate a habit of lifelong (un) learning
• ‘semper plangere’ (always complain) - and look for better evidence